Skip to main content
Fig. 2 | EJNMMI Research

Fig. 2

From: Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer

Fig. 2

Boxplots of tumour-to-liver ratios and tumour-to-mediastinum ratios in [68Ga]Ga-PSMA-11 PET and [18F]F-DCFPyL PET. The top row (A + B) is based on OSEM and the bottom row (C + D) is based on HD/UHD reconstructed PET data. Tumour-to-liver ratios (A + C) and tumour-to-mediastinum ratios (B + D) were calculated using either the maximum or mean SUV of the tumour lesion or the mean SUV of the background region. Boxplots depict minimum, first quartile, median, third quartile and maximum as well as outliers (circles, number equals lesion ID). In general, these boxplots show that the different tumour-to-liver ratios and tumour-to-mediastinum ratios are comparable for [68Ga]Ga-PSMA-11 PET and [18F]F-DCFPyL PET. Wilcoxon matched-pair signed-rank test found no significant differences for OSEM as well as for HD/UHD-based ratios. OSEM ordered subset expectation maximisation, HD high definition, UHD ultra-high definition, PET positron emission tomography, SUV standardised uptake values corrected for body weight, SUVmaxT/SUVmeanL Ratio of the maximum SUV in the tumour lesion to the mean SUV in the liver, SUVmeanT/SUVmeanL Ratio of the mean SUV in the tumour lesion to the mean SUV in the liver, SUVmaxT/SUVmeanM Ratio of the maximum SUV in the tumour lesion to the mean SUV in the mediastinum, SUVmeanT/SUVmeanM Ratio of the mean SUV in the tumour lesion to the mean SUV in the mediastinum, 68Ga [68Ga]Ga-PSMA-11, 18F [18F]F-DCFPyL

Back to article page